RAC 2.92% $1.94 race oncology ltd

General Comments / Chat, page-4892

  1. 1,954 Posts.
    lightbulb Created with Sketch. 321
    If that's the case, I'd say it's worse for Amgen for not waiting. We're practically in the clinic, could patent our own coformulated drug and possibly be approved for a number of years before they can get their partnership through.

    Or alternatively, any competitors.

    i think waiting is still in our favour.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.